Education
About Us
Working with TipRanks
Follow Us
Syros Pharmaceuticals (SYRS)
OTHER OTC:SYRS
SYRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $6.93
Previous CloseN/A
Volume1.14M
Average Volume (3M)45.22M
Market Cap
$652.03K
Enterprise Value$86.52M
Total Cash (Recent Filing)$49.89M
Total Debt (Recent Filing)$31.00K
Price to Earnings (P/E)―
Beta2.24
Next Earnings
May 01, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.03
Shares Outstanding26,832,457
10 Day Avg. Volume404,651
30 Day Avg. Volume45,223,166
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.26
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap132.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.26
Enterprise Value/Ebitda-0.95
Forecast
1Y Price Target
$1.00Price Target Upside4900.00% Upside
Rating ConsensusHold
Number of Analyst Covering0
---
Syros Pharmaceuticals News
PremiumPre-Earnings
Is SYRS a Buy, Before Earnings?
PremiumCompany Announcements
Syros Pharmaceuticals Delists from Nasdaq Amid Restructuring
PremiumCompany Announcements
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges---
Bulls Say, Bears Say
Bulls Say
Market OpportunityManagement highlighted the large commercial opportunity for tamibarotene in RARA-positive HR-MDS, with a market opportunity of ~$1.6Bn, >$800MM in RARA positive patients.
Therapeutic PotentialTamibarotene would be the first targeted therapy for the patient population, addressing the ~50% of patients with RARA overexpression.
Trial ContinuationThe SELECT-MDS-1 Phase 3 trial has passed an interim futility analysis, indicating the trial should continue without modification.
Bears Say
Clinical Trial FailureThe Phase 3 SELECT-MDS-1 trial did not achieve its primary endpoint of complete response rate, leading to the decision to remove tamibarotene from valuation.
Financial InstabilityThe failure to meet the primary endpoint in the SELECT-MDS-1 trial triggers an event of default under the secured loan agreement with Oxford Finance LLC.
Stock Valuation DeclineThe stock traded down about 86% in the aftermarket, reflecting a significant decline in valuation.
---
Ownership Overview
10.40% Insiders
1.61% Mutual Funds
18.02% Other Institutional Investors
69.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SYRS FAQ
What was Syros Pharmaceuticals’s price range in the past 12 months?
Syros Pharmaceuticals lowest stock price was $0.01 and its highest was $6.93 in the past 12 months.
What is Syros Pharmaceuticals’s market cap?
Syros Pharmaceuticals’s market cap is $652.03K.
When is Syros Pharmaceuticals’s upcoming earnings report date?
Syros Pharmaceuticals’s upcoming earnings report date is May 01, 2025 which is in 19 days.
How were Syros Pharmaceuticals’s earnings last quarter?
Syros Pharmaceuticals released its earnings results on Mar 06, 2025. The company reported -$0.65 earnings per share for the quarter, the consensus estimate of -$0.65 by $0.
Is Syros Pharmaceuticals overvalued?
According to Wall Street analysts Syros Pharmaceuticals’s price is currently Undervalued.
Does Syros Pharmaceuticals pay dividends?
Syros Pharmaceuticals does not currently pay dividends.
What is Syros Pharmaceuticals’s EPS estimate?
Syros Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does Syros Pharmaceuticals have?
Syros Pharmaceuticals has 26,832,457 shares outstanding.
What happened to Syros Pharmaceuticals’s price movement after its last earnings report?
Syros Pharmaceuticals reported an EPS of -$0.65 in its last earnings report, expectations of -$0.65. Following the earnings report the stock price went down -11.111%.
Which hedge fund is a major shareholder of Syros Pharmaceuticals?
Currently, no hedge funds are holding shares in SYRS
---
Company Description
Syros Pharmaceuticals
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
---
SYRS Stock 12 Month Forecast
Average Price Target
$1.00
▲(4900.00% Upside)
Technical Analysis
Biodexa Pharmaceuticals
―
Scorpius Holdings
―
TNF Pharmaceuticals
―
Hepion Pharmaceuticals
―
Windtree Therapeutics
―
Best Analysts Covering SYRS
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-57.53%
reiterated a buy rating 6 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -57.53% per trade.
---